Approval · Notice of Compliance 22032 · 2019
FORXIGA: Notice of Compliance 22032
Issued April 4, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22032
- Date
- April 4, 2019
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FORXIGA | Not yet assigned | — |
Medicinal ingredients
- DAPAGLIFLOZIN 5 MG per TAB
- DAPAGLIFLOZIN 10 MG per TAB